FDA approves Nerlynx to reduce risk of recurrent breast cancer

Tuesday, July 18, 2017 - 14:52 in Health & Medicine

The U.S. Food and Drug Administration today approved the use of Nerlynx to treat early-stage HER2-positive breast cancer to lower remission risk.

Read the whole article on UPI

More from UPI

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net